Both in Biotechnology
Hemab Therapeutics Holdings vs BioCryst Pharmaceuticals
Over the past year COAG returned +5.2% and BCRX returned +4.3%; their daily moves had a correlation of 0.36.
COAG +5.2% BCRX +4.3%Growth of $1, one year, split-adjusted
| Metric | COAG | BCRX |
|---|---|---|
| Price | $41.45 | $8.47 |
| Market cap | $1.94B | $2.16B |
| Today | +2.55% | −0.59% |
| 1 month | +33.5% | +4.3% |
| 6 months | — | −7.8% |
| Year to date | — | +8.6% |
| 1 year | — | +15.9% |
| Revenue growth (YoY) | — | +33.6% |
| Gross margin | — | 98.2% |
| Net margin | — | 35.9% |
| P/E (TTM) | — | — |
| Price / sales | — | 2.3× |
| Net cash | $457.5M | -$471.6M |
| Dividend yield | — | — |
| Volatility (60d) | — | 45.1% |
| Short % of float | 20.4% | 10.9% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).